関: dihematoporphyrin ether、porfimer、porfimer sodium

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/08/25 05:40:12」(JST)

wiki en

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units.^[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.^[2]

Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

Approvals and indications

It was approved in Canada in 1993 for the treatment of bladder cancer.^[2] It was approved in Japan in 1994 (for early stage lung cancer?).^[2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.^[2]

In August 2003 the FDA approved its use for Barrett's esophagus.^[3]

References

^ "Porfimer injection Prescribing information" (PDF).
^ ^a ^b ^c ^d "Photodynamic Therapy (PDT) for Lung Cancers". 2006.
^ "FDA Patient Safety News: Show #20, October 2003". October 2003. Retrieved 2009-08-17.

External links

Photofrin
Photofrin marketing info
Side effects of PDT with Photofrin
History of Photofrin

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肺癌の光線力学療法 photodynamic therapy of lung cancer
2. バレット食道のアブレーションのための光線力学療法 photodynamic therapy for ablation of barretts esophagus
3. 早期胃癌：治療、自然経過、および予後 early gastric cancer treatment natural history and prognosis
4. 光線過敏症（光線皮膚症）：臨床症状、診断、および治療 photosensitivity disorders photodermatoses clinical manifestations diagnosis and treatment
5. 筋層非浸潤性膀胱癌の治療 treatment of non muscle invasive bladder cancer

English Journal

Severe acute airway obstruction and respiratory failure with fibrous plug following photodynamic therapy (PDT): indication for early bronchoscopy and debridement.

Khan AM1, Pipkin M1, Mozayyan S1, Hwang D1, Yasufuku K2.
Photodiagnosis and photodynamic therapy.Photodiagnosis Photodyn Ther.2014 Jun;11(2):254-8. doi: 10.1016/j.pdpdt.2014.02.004. Epub 2014 Feb 27.
INTRODUCTION: PDT is a safe procedure with most post procedural complications reported as minor. We report a case of severe acute stridor and trachea-bronchial airway obstruction with mucosal sloughing and fibrous plugs resulting in respiratory failure within three hours following PDT. To our knowle
PMID 24583093

In vitro multiwavelength PDT with 3IL states: teaching old molecules new tricks.

Yin H1, Stephenson M, Gibson J, Sampson E, Shi G, Sainuddin T, Monro S, McFarland SA.
Inorganic chemistry.Inorg Chem.2014 May 5;53(9):4548-59. doi: 10.1021/ic5002368. Epub 2014 Apr 11.
The purpose of the present investigation was to ascertain whether (3)IL excited states with microsecond lifetimes are universally potent for photodynamic applications, and if these long-lived states are superior to their (3)MLCT counterparts as in vitro PDT agents. A family of blue-green absorbing,
PMID 24725142

Imbalance of Ca2+ and K+ fluxes in C6 glioma cells after PDT measured with scanning ion-selective electrode technique.

Hu SL1, Du P, Hu R, Li F, Feng H.
Lasers in medical science.Lasers Med Sci.2014 May;29(3):1261-7. doi: 10.1007/s10103-014-1518-3. Epub 2014 Jan 24.
Photodynamic therapy (PDT) possesses the capacity to lead to death of C6 glioma in vitro and in vivo. The purpose of this study was to investigate whether Ca(2+) and K(+) homeostasis of C6 glioma cells were affected by PDT. C6 glioma cells were randomly divided into five groups: control group, Hemat
PMID 24458531

Japanese Journal

高効率LEDによる光照射とビリルビン添加による白血病細胞増殖抑制

白井僚,岡本研正,服部哲郎,平田裕子,山口文徳,徳田雅明
電気学会論文誌. C 134(11), 1603-1612, 2014
… The PDT is utilized for lung cancer and skin disease and it combines a photosensitive agent, e.g. Photofrin or Laserphyrin, and laser with a particular wavelength. …
NAID 130004704413

Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia

Ikeda Hisazumi,Tobita Takayoshi,Ohba Seigo,Uehara Masataka,Asahina Izumi
Photodiagnosis and Photodynamic Therapy 10(3), 229-235, 2013-09
… However, few studies have examined the use of Photofrin-mediated PDT to manage early carcinoma and dysplasia in the oral cavity. … Methods: Between January 2004 and November 2008, 25 T1 to T2 patients with N0 oral squamous cell carcinoma and mucosal dysplasia in the oral cavity were treated by Porfimer sodium (Photofrin®)-mediated PDT at Nagasaki University Hospital. …
NAID 120005345404

超高齢者胃がんに対する光線力学診断・治療−Talaporfin Sodium（Laserphyrin®）の有用性−

中村哲也,生沼健司
日本レーザー医学会誌 34(2), 124-131, 2013
2009 年から2011 年にかけて，手術や他の根治治療が困難な噴門部胃がんに対して，1 回のフォトフリン® を用いた光線力学治療（photodynamic therapy: PDT）と3回のレザフィリン® を用いた光線力学診断（photodynamic diagnosis: PDD）およびPDT を行った87 歳の超高齢患者を対象とし，PDT を中心とした内視鏡治療の効果および偶発症，フォトフリ …
NAID 130004893572

Related Pictures

★リンクテーブル★

リンク元	「ポルフィマー」「dihematoporphyrin ether」「porfimer」

「ポルフィマー」

Porfimer sodium
Clinical data
AHFS/Drugs.com	Consumer Drug Information
License data	EU EMA: by INN; US FDA: Photofrin;
Pregnancy; category	US: C (Risk not ruled out); ;
Routes of; administration	Intravenous
ATC code	L01XD01 (WHO);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	NA
Protein binding	~90%
Biological half-life	21.5 days (mean)
Excretion	Fecal
Identifiers
CAS Number	97067-70-4 87806-31-3;
PubChem CID	57166;
DrugBank	DB00707 ;
ChemSpider	10482283 ;
UNII	Y3834SIK5F;
ChEMBL	CHEMBL1201707 ;
Chemical and physical data
Formula	C68H74N8O11 (for n=0)
Molar mass	1179.36 g/mol (for n=0)
3D model (JSmol)	Interactive image;
	SMILES [Na+].OC(=O)CC\C2=C(/C)c1cc%10nc(cc4nc(cc3nc(cc2n1)c(CCC(O)=O)c3C)/C(=C4/C)C(C)OC(C)c9c5nc(cc8nc(cc7nc(cc6nc(c5)C(\C)=C6\C(C)O)c(C)c7CCC(O)=O)C(\CCC(O)=O)=C8\C)c9C)c(C(C)O)c%10C ;
	InChI InChI=1S/C68H74N8O11.Na/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50;/h21-28,37-40,71-73,75,77-78H,13-20H2,1-12H3,(H,79,80)(H,81,82)(H,83,84)(H,85,86);/q;+1/b45-21-,46-22-,47-23-,48-24-,49-21-,50-22-,51-26-,52-25-,53-28-,54-27-,55-27-,56-28-,57-23-,58-25-,59-24-,60-26-; ; Key:CGQHMICGJYKFFJ-ZLJVSRBASA-N ;
(what is this?) (verify)